The Abbott baby formula recall has been a major issue affecting parents and caregivers across the United States. Here is a comprehensive overview of the key events and implications of the recall.
Overview of Abbott Baby Formula Recall
In February 2022, Abbott Laboratories issued a voluntary recall of certain lots of Similac, Alimentum, and EleCare powdered infant formulas manufactured at its Sturgis, Michigan plant. This recall was initiated after the FDA received complaints of Cronobacter sakazakii infections in infants who had consumed formula from this plant. Two infants tragically passed away, though the FDA noted there was no conclusive evidence linking Abbott's formulas to these illnesses.
The recall was expanded in March 2022 to include additional lots of Similac PM 60/40. Affected products can be identified by the lot code on the bottom of the container, which will have a number starting with 22 through 37, contain K8, SH, or Z2, and have an expiration date of April 1, 2022 or later.
FDA Investigation and Findings
The FDA began investigating the Sturgis plant in January 2022 after receiving a whistleblower complaint alleging safety violations, including employees falsifying records and failing to properly test formula before release. Inspections in January and February 2022 found issues such as standing water, unclean surfaces, and a history of Cronobacter contamination at the facility.
In March 2022, the FDA made public the 483 inspection report detailing these findings. Abbott responded that while corrective actions were needed, no Cronobacter or Salmonella was found in products distributed to consumers. The company submitted a response and corrective action plan to the FDA in April 2022.
Consent Decree and Restart of Production
In May 2022, the FDA reached an agreement with Abbott in the form of a consent decree to reopen the Sturgis plant. This required Abbott to notify the FDA of any Cronobacter findings, store samples, and make facility improvements overseen by a qualified expert. Violations could result in fines up to $30,000 per day, capped at $5 million annually.
Under this agreement, Abbott restarted production of EleCare and other specialty metabolic formulas in July 2022, with initial product release by late June. Similac production resumed in August 2022. Abbott stated it would work to re-earn the trust of parents and caregivers who have relied on its formulas for over 50 years.
Impact and Shortage
The recall exacerbated an existing industry-wide infant formula shortage in the U.S. Parents faced empty shelves and struggled to find alternatives, sometimes resorting to feeding their infants cereal, juice, or formula not suitable for their age. The shortage became a political issue, with calls for investigations and hearings to review what went wrong.
To help ease the shortage, the FDA took steps to increase formula imports from other countries. Abbott also worked to boost production at its other facilities and import Similac from its Ireland plant. By June 2022, Abbott was producing 8.7 million pounds of formula for the U.S. market.
Ongoing Investigations and Lawsuits
In January 2023, the Justice Department's consumer protection branch began investigating Abbott regarding its Sturgis plant. The SEC and FTC also launched investigations into Abbott's infant formula business in February 2023.
Parents have filed lawsuits against Abbott and other formula makers like Mead Johnson, alleging their cow's milk formulas increased the risk of necrotizing enterocolitis (NEC) in premature infants. These are separate from the Cronobacter recall lawsuits.
In March 2023, the FDA sent letters to formula manufacturers with recommendations for preventing future Cronobacter illnesses. The agency noted that while rare, Cronobacter infections can be life-threatening for infants, causing sepsis and meningitis.
Conclusion
The Abbott baby formula recall has had far-reaching impacts, from the tragic illnesses and deaths of infants to the nationwide shortage that left parents desperate to feed their children. It has revealed gaps in regulation and reporting of formula safety issues.
While production has resumed at the Sturgis plant, investigations into the root causes of the contamination and the company's actions are ongoing. The recall has also spurred lawsuits and calls for greater accountability and oversight in the infant formula industry.
As the U.S. works to rebuild formula supplies and prevent future shortages, the safety of these critical products remains paramount. Parents and caregivers must remain vigilant in checking for recalled products and consult with their pediatricians on safe alternatives. Regulators and manufacturers alike must prioritize the health and well-being of infants above all else.
Frequently Asked Questions
Contact Us
Client Reviews
Awards and Organizations
Free Consultations
No Fees or Costs Unless we Win your Personal Injury Case!